Cumulative evidence suggest that early life bronchiolitis is a major risk factor for subsequent wheezing episodes and asthma. The purpose of this review is to present the recent findings and current perspectives regarding the interplay between bronchiolitis and long-term respiratory outcomes.
INTRODUCTION
Viral bronchiolitis in infancy has been known for decades to be an antecedent for subsequent wheezing and asthma during childhood. However, recent reports suggest that the risk for asthma following bronchiolitis may be higher than was previously estimated, and that this association may persist into early adulthood. Previously, most of the research in this field focused on the role of Respiratory Syncytial Virus (RSV) in the inception of asthma. However, advancements in molecular viral diagnostic techniques have allowed detection of previously undetectable or difficult to detect respiratory viruses, and have led to the increased recognition of the role of human rhinovirus (HRV) lower-respiratory tract infection (LRTI) in asthma inception. This review discusses the recent evidence and concepts regarding the role of early life viral bronchiolitis and future asthma.
THE ROLE OF RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS IN THE INCEPTION OF ASTHMA
The cohort established by Sigurs et al. [1] remains the longest prospective longitudinal cohort that has investigated the consequences of severe RSV bronchiolitis in infancy in terms of the development of subsequent recurrent wheeze and asthma. This Swedish cohort enrolled 47 infants with severe RSV bronchiolitis. For the purpose of this review, the term severe RSV bronchiolitis refers to an episode of bronchiolitis severe enough to require hospitalization. All infants enrolled were younger than 1 year of age at the time of the hospitalization, and more than 90% were younger than 6 months. Ninety-three age-matched and sex-matched children were recruited as controls. Children who experienced severe RSV bronchiolitis had a greater prevalence of asthma/recurrent wheezing (three or more episodes) and allergic sensitization at the ages of 3, 7, and 13 years compared with the control cohort. The most recent report from this cohort [2 && ] demonstrated that the association between severe RSV bronchiolitis and the outcomes of asthma and atopy persists into early adulthood. At the age of 18 years, significantly higher prevalences of the following outcomes were noted in the RSV bronchiolitis cohort compared with controls: asthma/recurrent wheeze (39 vs. 9%), clinical allergic rhinoconjunctivitis (43 vs. 17%), and sensitization to perennial allergens (41 vs. 14%). Only severe RSV bronchiolitis in infancy and current allergic rhinoconjunctivitis were found to be significant predictors for current asthma/recurrent wheeze. In addition, at the age of 18 years, patients with a history of RSV bronchiolitis had lower pulmonary function (FEV 1 , FEV 1 /FVC ratio), greater airway hyper-responsiveness, and greater bronchodilator response. These indicators of airway obstruction could already be detected at the age of 7 and 13 years. Although reduced spirometry indices among RSV patients were independent of current diagnosis of asthma/recurrent wheeze, small airway dysfunction measured by lung clearance index was lower among patients with a current diagnosis of asthma. Overall, these findings demonstrate that severe RSV bronchiolitis early in life is associated with an increased risk for asthma, airway hyper-responsiveness, and allergic sensitization, suggesting that this association might last into early adulthood.
This finding of a persistently elevated risk for asthma in adulthood after severe RSV bronchiolitis [1] differs from the effects reported by Stein et al. [3] , who found that RSV bronchiolitis in the Tucson Children's Respiratory Study (TCRS) was an independent risk factor for the subsequent development of wheezing up to age 11 years, but this risk became nonsignificant by the age of 13 years. However, the children in the TCRS cohort had less severe RSV bronchiolitis, as they experienced predominantly outpatient episodes. These differences in long-term outcome may be a reflection of a differential relationship of bronchiolitis severity on subsequent respiratory disease, as demonstrated by a recent study by Carroll et al. [4] . They noted a gradient of increasing risk of asthma following bronchiolitis based upon the level of heath care utilization (i.e. ambulatory clinic visit vs. emergency department visit vs. hospitalization) during bronchiolitis, with the greatest risk of asthma following bronchiolitis hospitalization [4] .
The RSV Bronchiolitis in Early Life (RBEL) study [5 && ], a prospective cohort of infants hospitalized for RSV bronchiolitis focused on the identification of determinants of post-RSV asthma, recently reported asthma-related outcomes in the 6 years following the initial infection. Among the 206 children enrolled with severe RSV bronchiolitis during the first year of life, 48% had received a physician diagnosis of asthma by the seventh birthday. Risk factors for an asthma diagnosis were identifiable during the first year of life, with maternal asthma and high levels of dog allergen exposure being associated with an increased risk of asthma, whereas Caucasian ethnicity and daycare attendance were associated with decreased risk of asthma. Allergic sensitization at age 3 years was also associated with an increased risk of physician diagnosis of asthma. The authors identified a biological predictor of post-RSV asthma; greater levels of nasal epithelial expression of the chemokine CCL5 during acute bronchiolitis were strongly predictive of physician-diagnosed asthma by the seventh birthday. These findings support severe RSV bronchiolitis as a substantial risk factor for asthma by school age and identify a novel biological predictor for asthma risk, namely nasal CCL5 expression.
THE ROLE OF NON-RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS IN THE INCEPTION OF ASTHMA
Recent advances in virologic detection methodologies have led to the identification of additional non-RSV viral-induced LRTIs in early childhood, particularly HRV, as important risk factors for future asthma.
Valuable insight on the association between early life HRV LRTI and the risk of future asthma was reported from the Childhood Origin of Asthma (COAST) project. COAST is a birth cohort study [6] of infants at high risk for allergic diseases and/or asthma based on parental history of respiratory allergies and/or a history of physician-diagnosed asthma. Two hundred and thirty-eight children have been followed up to the age of 8 years [6] . The investigators collected data on the causative virus for each LRTI in this cohort, and previously reported that HRV LRTIs during the first year of life,
KEY POINTS
The risk for asthma following severe RSV bronchiolitis may be higher than was previously estimated, and this association might last into early adulthood.
Emerging data suggest that non-RSV bronchiolitis, and mainly HRV bronchiolitis, is a major risk factor for future asthma.
Whether bronchiolitis is related to future asthma causality or serves as a marker of asthma predisposition remains uncertain. even though most were outpatient LRTIs, were a significant predictor of asthma at age 6 years [7] . A recent report from this group suggested that the occurrence of a HRV-associated wheezing illness in the first 3 years of life was associated with an obstructive lung function pattern at age 5-8 years, while small airway dysfunction at school age was not associated early life wheezing episodes triggered by RSV or other respiratory viruses [8] . It should be noted that COAST is a cohort of children at increased risk of developing asthma; therefore, these findings may not necessarily be applicable to the general population. Nevertheless, these findings provide additional support of the association between early life HRVassociated wheezing and future asthma.
Until recently, most of the evidence regarding the association between early life human HRV LRTI and future asthma was based largely on outpatient cohorts [9] [10] [11] , with limited data available on the association between inpatient HRV LRTI and future wheezing and asthma [12] . Three recent publications from Europe [13,14,15 & ] present new information regarding the association between non-RSV severe bronchiolitis and future wheezing episodes and/or asthma. Midulla et al. [15 & ] investigated risk factors for two or more episodes of wheezing during the year following hospitalization for viral bronchiolitis. Within 3 days of hospitalization, nasal washes were assayed for nucleic acid from 14 respiratory viruses. The study population included 313 infants, all younger than 1 year, who were hospitalized with a first episode of viral LRTI. All children were recruited between the months of October to May over five consecutive years. An additional 39 infants without acute respiratory disease were recruited as controls. The rate of recurrent wheezing was highest after HRV bronchiolitis compared with other respiratory viruses: 80% for HRV, 67% for human Bocavirus (hBoV), 50% for other viruses, 46% for RSV and hBoV, and 44% for RSV. Independent risk factors for recurrent wheezing were HRV infection (although marginally significant), and a positive family history for asthma. Koponen et al. [13] followed 166 children hospitalized for viral bronchiolitis before the age of 6 months for 6 years. The overall asthma prevalence was 13% in this cohort, but it was significantly higher in non-RSV patients (24%) than in RSV patients (8%). Fourteen percent of former HRV patients were diagnosed with asthma. Atopic dermatitis, non-RSV bronchiolitis, and maternal asthma were independent significant early-life predictors for asthma in this cohort. Mikalsen et al. [14] followed children for 11 years after hospitalization for viral bronchiolitis in the first year of life. This study identified RSV as the causative virus in 74% of the children, but did not examine for evidence of other viruses. As compared with a group of unselected age-matched controls, hospitalized children had a higher prevalence of asthma, an obstructive lung function pattern, and greater bronchial hyper-responsiveness. However, asthma prevalence was significantly higher only after RSV-negative bronchiolitis, and the obstructive lung function pattern was most prominent after RSV-negative bronchiolitis [14] .
Taken together, these three recent studies [13,14,15 & ] highlight the emerging importance of severe non-RSV bronchiolitis early in life as a major risk factor for future wheezing and/or asthma. In addition, the rates of asthma following severe non-RSV bronchiolitis in infancy among these European cohorts are generally lower than was recently reported in a US cohort following severe RSV bronchiolitis [5 && ]. Potential explanations for these differences include study population characteristics such as social/environmental factors including maternal stress [16] [17] [18] and exposure to pollution [19] that might have modifying roles on the interaction between early life bronchiolitis and asthma.
VIRAL BRONCHIOLITIS IN EARLY INFANCY AND FUTURE ASTHMA: 'THE CHICKEN AND THE EGG' DILEMMA
As described above, abundant evidence supports an association between early life viral bronchiolitis and future asthma. However, it remains uncertain whether severe bronchiolitis early in life is the cause of future asthma or serves as a marker for susceptibility to bronchiolitis that identifies children with asthma predisposition.
Evidence from murine models of viral bronchiolitis suggests that the viral infection can induce allergic predisposition. It was shown that murine parainfluenza LRTI causes an upregulation of the high-affinity IgE receptor on lung antigen presenting cells, production of Th2 inflammatory cell and inflammatory mediators, and eventually results in an increased immune response to inhalant allergens [20,21 && ,22-24] . The importance of the viral infection as the initial event ('the first hit') to create airway allergic inflammation was further demonstrated in additional models involving innate immunity and invariant natural killer T cells [25, 26] . All together, these findings obtained in animal models of bronchiolitis highlight the importance of an interaction between viral infection and inhalant allergen exposure: the viral infection is able to set the appropriate pro-allergic milieu, and if within the appropriate time-frame the animal is exposed to inhalant allergens, then allergenspecific airway inflammation may develop.
Previous epidemiological data also support a direct causal role of RSV infection in the pathogenesis of asthma [27] , with a recent report showing that provision of RSV prophylaxis with palivizumab to premature infants without a family history of asthma and/or atopy reduced the risk of recurrent wheezing between the ages of 2 and 5 years by 80% [28] . Interestingly, such a protective effect was not found among preterm infants with atopic backgrounds, suggesting that different mechanisms may be at play in the inception of asthma based on the atopic background of the child [28] .
In contrast to the evidence supporting a direct causal role of viral bronchiolitis in the pathogenesis of asthma, two previous epidemiologic studies conducted among monozygotic twin pairs, discordant for severe RSV bronchiolitis in infancy, did not support the theory that RSV bronchiolitis causes asthma [29, 30] . Poorisrisak et al. [30] did not detect a difference in pulmonary function, exhaled nitric oxide levels, asthma prevalence, asthma medication use, or sensitization between monozygotic twins discordant for RSV bronchiolitis hospitalization in infancy who were studied at a mean age of 7.6 years. Thomsen et al. [29] used genetic variance components models and direction of causation models in 8280 pairs of twins and concluded that severe RSV bronchiolitis most likely represents a genetic predisposition to asthma. In addition, two recent studies support the position that viral LRTI is a marker for atopic predisposition and not the cause of future wheezing and asthma. A report [31 && ] from the COAST project aimed to determine the developmental sequence of allergic sensitization and viral wheeze. By using a longitudinal evaluation of this cohort, allergic sensitization to aeroallergens, beginning at the first year of life, was identified as a significant risk factor for viral induced wheeze, and this was significant for HRV but not for RSV. However, having viral wheeze did not increase the risk of developing allergic sensitisation [31 && ]. Another report [32] from the Copenhagen Prospective Study of Asthma in Childhood birth cohort, a high risk cohort of infants born to mothers with asthma, also suggested that severe bronchiolitis is a result of preexisting susceptibility of the airway to react to viral infections. These investigators measured infant lung function and bronchial responsiveness to methacholine at the age of 1 month and before the infants had any respiratory symptoms. Children who later had acute severe bronchiolitis had a 2.5-fold increased responsiveness to methacholine at the age of 1 month [32] . Taken together, these two studies suggest that allergic sensitization and/or airway dysfunction may serve as predisposing factors that increase host susceptibility to viral bronchiolitis. Therefore, in these cohorts, the occurrence of viral bronchiolitis appears to be a reflection of predisposition to wheeze with viral infections rather than the viral infection serving as a causative factor for subsequent asthma. However, it should be noted that the high-risk nature of these two birth cohorts decreases the generalizability of these findings to nonhigh-risk populations, and it remains possible that viral bronchiolitis precedes the development of airway dysfunction among children without atopic predispositions.
It is probable that these two scenarios, bronchiolitis as either a cause or a marker for asthma theories, are not mutually exclusive. Children who wheeze in early life because of HRV differ from those who wheeze in early life due to RSV: they are older and more likely to have personal and family history of asthma [33, 34] . These differences in underlying atopic backgrounds influencing the likelihood of wheezing in the context of different viral infections suggest that two different pathways may exist: HRV-induced wheeze (most likely to occur in the outpatient setting) might be more of a marker for asthma tendency, while RSV (especially more severe disease warranting hospitalization) might have a more causative role in the pathogenesis of disease. This postulate could be supported by the successful wheezing prevention conferred by RSV prophylaxis with palivizumab only among nonatopic children, suggesting a different consequence of the viral infection depending on atopic predisposition [28] . Additional evidence that these two respiratory viruses might have different roles in the pathogenesis of asthma was recently provided by the Tennessee Children's Respiratory Initiative [35] . In this study, the investigators aimed to determine whether maternal asthma was associated with a higher risk of infant respiratory tract infection with HRV vs. RSV, and whether maternal asthma was associated with increased infection severity. They reported that having a mother with atopic asthma significantly increased the risk of the infant experiencing HRV infection compared with RSV infection, and maternal asthma increased the severity of infant HRV infection but not the severity of RSV infection. These findings support the hypothesis that, compared with infants with RSV infection, infants with HRV infections are more likely to have an atopic predisposition reflected by positive family history; and it might be that this atopic predisposition modulates the increased risk for asthma among children who wheeze with HRV [35] .
VITAMIN D STATUS AS A POTENTIAL MODIFYING FACTOR OF THE RELATIONSHIP BETWEEN VIRAL INFECTIONS AND ASTHMA INCEPTION
Although severe bronchiolitis in infancy is a major risk factor for the development of recurrent wheezing and asthma, it is clear that not all infants who have severe viral bronchiolitis will develop subsequent recurrent wheezing and/or asthma. Therefore, additional host factors, such as atopic predisposition, allergic sensitization, immune response factors, and illness severity, along with environmental exposures might serve as modifying factors for the risk of developing asthma [20, 33] . Vitamin D has emerged as a potential factor that may modulate asthma severity and activity. Recent reports showed that low serum vitamin D levels are associated with increased asthma severity and poor asthma control among school age children and adolescents [36] [37] [38] [39] [40] [41] [42] . Among younger children, vitamin D may be a modifying factor for the progression from viral bronchiolitis to asthma through multiple mechanisms: in-utero effects on lung growth and maturation, enhancement of viral immunity and as a result prevention and/or attenuation severity of viral bronchiolitis, and attenuation of allergic sensitization [43 && ]. Three recent studies revealed that maternal vitamin D levels during pregnancy [44] , or in cord blood [45, 46] are inversely associated with the risk of viral respiratory tract illness (RTI) during the first year of life. The most relevant evidence was provided by Belderbos et al. [45] who reported a six-fold increased risk of RSV LRTI during the first year of life among infants with cord blood vitamin D levels below 50 nmol/l (20 ng/ml) compared with infants with adequate [>75 nmol/l (30 ng/ml)] cord blood vitamin D levels. However, although these studies provide evidence for the potentially protective effects of higher vitamin D levels for the prevention of RTI, there were conflicting results regarding the effect of maternal serum vitamin D levels on the risk of future wheezing episodes during early childhood. Although one study [46] showed that lower cord blood vitamin D levels were associated with higher risk of wheezing episodes (but not with the diagnosis of asthma), another study [44] failed to confirm this association. However, the timing of maternal vitamin D measures differed between the studies, in the study [46] that reported a protective effect of vitamin D, levels were measured in cord blood while in the negative study [44] , levels were measured during pregnancy, which might result in a less accurate estimation of vitamin D status in the newborn. In addition, two studies [47, 48] did not find an association between child's serum vitamin D levels and the risk of hospitalization for viral LRTI; however, one of these studies [47] suggested that vitamin D might modify the severity of the acute LRTI, as mean vitamin D level among LRTI patients admitted to the ICU was significantly lower than that observed in patients admitted to the general pediatrics ward. Taken together, these studies suggest that adequate vitamin D levels at birth might prevent early life viral infection; however, the consequence of vitamin D status on subsequent wheezing episodes remains unclear, and ongoing trials of maternal vitamin D supplementation will hopefully clarify this situation. No data are currently available to determine if adequate serum vitamin D levels in early infancy can prevent severe bronchiolitis requiring hospitalization or the respiratory outcomes that follow this event.
CONCLUSION
Recent evidence supports the importance of early life viral bronchiolitis in the developmental pathway of asthma. Multiple specific viral respiratory infections appear to serve as antecedents to childhood asthma, and future research is certain to identify additional viral pathogens, which precede or signal the development of asthma. The dilemma of whether bronchiolitis early in life is the cause of future asthma or a marker for susceptibility for asthma is not yet resolved; most likely both of these pathways are relevant, and there may be differential effects based on the child's atopic predisposition and the specific virus. Finally, host and environmental factors likely modify the risk of asthma following early life bronchiolitis, and further research is needed to explore the potential roles of modifiable factors, such as vitamin D status, on these processes and outcomes.
